| Year |
Citation |
Score |
| 2024 |
Lee H, Horbath A, Kondiparthi L, Meena JK, Lei G, Dasgupta S, Liu X, Zhuang L, Koppula P, Li M, Mahmud I, Wei B, Lorenzi PL, Keyomarsi K, Poyurovsky MV, et al. Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nature Communications. 15: 79. PMID 38167301 DOI: 10.1038/s41467-023-44412-7 |
0.349 |
|
| 2023 |
Lulla AR, Akli S, Karakas C, Caruso JA, Warma LD, Fowlkes NW, Rao X, Wang J, Hunt KK, Watowich SS, Keyomarsi K. Neutrophil elastase remodels mammary tumors to facilitate lung metastasis. Molecular Cancer Therapeutics. PMID 37796181 DOI: 10.1158/1535-7163.MCT-23-0414 |
0.39 |
|
| 2023 |
Wingate HF, Keyomarsi K. Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Research. 83: 3165-3167. PMID 37779425 DOI: 10.1158/0008-5472.CAN-23-2608 |
0.748 |
|
| 2023 |
Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Research. PMID 37384539 DOI: 10.1158/0008-5472.CAN-23-0705 |
0.796 |
|
| 2023 |
DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Ileana Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, et al. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37279095 DOI: 10.1158/1078-0432.CCR-23-0103 |
0.397 |
|
| 2023 |
Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, ... Keyomarsi K, et al. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. Jama Oncology. PMID 36892847 DOI: 10.1001/jamaoncol.2022.7949 |
0.398 |
|
| 2023 |
Nguyen TDT, Wang Y, Bui TN, Lazcano R, Ingram DR, Yi M, Vakulabharanam V, Luo L, Pina MA, Karakas C, Li M, Kettner NM, Somaiah N, Houghton PJ, Mawlawi O, ... ... Keyomarsi K, et al. Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time. Cancer Research. PMID 36603130 DOI: 10.1158/0008-5472.CAN-22-2258 |
0.321 |
|
| 2022 |
Li M, Tsavachidis S, Wang F, Bui T, Nguyen TDT, Luo L, Multani AS, Bondy ML, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene. PMID 36344674 DOI: 10.1038/s41388-022-02527-z |
0.509 |
|
| 2022 |
Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, ... ... Keyomarsi K, et al. CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Research. PMID 35771632 DOI: 10.1158/0008-5472.CAN-22-0631 |
0.341 |
|
| 2022 |
Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opinion On Investigational Drugs. 31: 607-631. PMID 35435784 DOI: 10.1080/13543784.2022.2067527 |
0.377 |
|
| 2021 |
Lulla AR, Akli S, Karakas C, Ha MJ, Fowlkes NW, Mitani Y, Bui T, Wang J, Rao X, Hunt KK, Meijer L, El-Naggar AK, Keyomarsi K. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 10: 40. PMID 33990543 DOI: 10.1038/s41389-021-00324-z |
0.424 |
|
| 2021 |
Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or Alteration. Cancers. 13. PMID 33916118 DOI: 10.3390/cancers13071656 |
0.473 |
|
| 2020 |
Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40: 115-126. PMID 32421454 DOI: 10.1200/EDBK_281085 |
0.407 |
|
| 2020 |
Johnston SJ, Syed BM, Parks RM, Monteiro CJ, Caruso JA, Green AR, Ellis IO, Hunt KK, Karakas C, Keyomarsi K, Cheung KL. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers. 12. PMID 32197318 DOI: 10.3390/Cancers12030712 |
0.546 |
|
| 2020 |
Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. British Journal of Cancer. PMID 31942030 DOI: 10.1038/S41416-019-0707-Z |
0.529 |
|
| 2020 |
Navarro-Yepes J, Chen X, Bui T, Kettner NM, Hunt KK, Keyomarsi K. Abstract PD2-05: Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-05 |
0.527 |
|
| 2020 |
Kettner NM, Bui T, Ha MJ, Eckols TK, Tweardy DJ, Meric-Bernstam F, Hunt KK, Tripathy D, Keyomarsi K. Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-04-12 |
0.51 |
|
| 2020 |
Kettner NM, Bui T, Chen X, Hunt KK, Tripathy D, Keyomarsi K. Abstract P6-03-09: Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-03-09 |
0.399 |
|
| 2020 |
Mastoraki S, Navarro-Yepes J, Tran T, Sahin A, Hunt K, Navin N, Keyomarsi K. Abstract P4-06-03: Assessment of intratumoral heterogeneity in early stage estrogen receptor (ER) positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-06-03 |
0.468 |
|
| 2020 |
Lulla AR, Akli S, Chrisikos TT, Pina MA, Zhou Y, Li H, Watowich SS, Keyomarsi K. Abstract P3-10-02: Neutrophil elastase as a therapeutic target to inhibit metastasis in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-10-02 |
0.516 |
|
| 2020 |
Li M, Low KH, Bui T, Hunt KK, Keyomarsi K. Abstract P2-05-04: Low molecular weight cyclin E facilitates replication stress tolerance in breast cancer development Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-05-04 |
0.572 |
|
| 2019 |
Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgery. PMID 31436549 DOI: 10.1097/Sla.0000000000003551 |
0.801 |
|
| 2019 |
Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JP, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, ... ... Keyomarsi K, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30867218 DOI: 10.1158/1078-0432.Ccr-18-3274 |
0.5 |
|
| 2019 |
Johnston S, Parks R, Syed BM, Green AR, Hunt K, Keyomarsi K, Ellis IO, Cheung K. Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer. Journal of Clinical Oncology. 37: 3128-3128. DOI: 10.1200/Jco.2019.37.15_Suppl.3128 |
0.563 |
|
| 2019 |
Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Yang J, Yi M, Carey JP, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, ... ... Keyomarsi K, et al. Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-323 |
0.476 |
|
| 2019 |
Johnston S, Syed B, Parks R, Ellis I, Green A, Keyomarsi K, Hunt K, Leung C. CYTOPLASMIC CYCLIN E: AN EXQUISITE MARKER OF TUMOR BIOLOGY IN OLDER WOMEN WITH PRIMARY BREAST CANCER Journal of Geriatric Oncology. 10: S20. DOI: 10.1016/s1879-4068(19)31151-8 |
0.419 |
|
| 2019 |
Stauder M, Tereffe W, Shaitelman S, Smith B, Yeboa D, Reed V, Delclos M, Ibrahim N, Raghavendra A, Karuturi M, Keyomarsi K, Tripathy D, Woodward W. Toxicity of Radiation Therapy Given Concomitantly with Palbociclib for Metastatic Breast Carcinoma International Journal of Radiation Oncology*Biology*Physics. 105: E60. DOI: 10.1016/J.Ijrobp.2019.06.2399 |
0.361 |
|
| 2018 |
Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Research. PMID 30194068 DOI: 10.1158/0008-5472.Can-18-1235 |
0.52 |
|
| 2018 |
Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JP, Bui T, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, ... ... Keyomarsi K, et al. Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30181387 DOI: 10.1158/1078-0432.Ccr-18-1446 |
0.601 |
|
| 2018 |
Fu S, Wang Y, Keyomarsi K, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion On Investigational Drugs. 1-11. PMID 30102076 DOI: 10.1080/13543784.2018.1511700 |
0.415 |
|
| 2018 |
Xi Y, Shi J, Li W, Tanaka K, Allton KL, Richardson D, Li J, Franco HL, Nagari A, Malladi VS, Coletta LD, Simper MS, Keyomarsi K, Shen J, Bedford MT, et al. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. Bmc Genomics. 19: 150. PMID 29458327 DOI: 10.1186/S12864-018-4533-0 |
0.481 |
|
| 2017 |
Franco HL, Nagari A, Malladi V, Li W, Xi Y, Richardson D, Allton KL, Tanaka K, Li J, Murakami S, Keyomarsi K, Bedford MT, Shi X, Li W, Barton MC, et al. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Research. PMID 29273624 DOI: 10.1101/Gr.226019.117 |
0.556 |
|
| 2017 |
Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology. PMID 29218622 DOI: 10.1007/S11523-017-0541-2 |
0.558 |
|
| 2017 |
Carey JP, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. Cancer Research. PMID 29180466 DOI: 10.1158/0008-5472.Can-17-1494 |
0.594 |
|
| 2017 |
Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA, Suman V, Hunt K, Moulder-Thompson S, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28947566 DOI: 10.1158/1078-0432.Ccr-17-1544 |
0.593 |
|
| 2017 |
Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer. 8: 2004-2009. PMID 28819400 DOI: 10.7150/Jca.18196 |
0.477 |
|
| 2017 |
Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, ... ... Keyomarsi K, et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications. 8: 15916. PMID 28653662 DOI: 10.1038/Ncomms15916 |
0.62 |
|
| 2017 |
Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest. Molecular Cancer Therapeutics. PMID 28619757 DOI: 10.1158/1535-7163.Mct-17-0040 |
0.451 |
|
| 2017 |
Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. PMID 28107181 DOI: 10.18632/Oncotarget.14689 |
0.584 |
|
| 2017 |
Syed BM, Green AR, Morgan D, Ellis IO, Hunt K, Keyomarsi K, Cheung K. Relationships of cyclin E with clinical outcome and biomarkers in older women with early operable primary breast cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E12031 |
0.543 |
|
| 2017 |
Carey JP, Vjayaraghavan S, Hunt K, Keyomarsi K. Abstract A15: Downregulation of c-myc is synthetic lethal with PARP inhibitors in high MYC cancers independent of BRCA status Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A15 |
0.52 |
|
| 2017 |
Keyomarsi K, Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Hunt K, Tripahty D. Abstract P5-04-03: Palbociclib synergizes with autophagy inhibitors to induce senescence in breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-04-03 |
0.532 |
|
| 2017 |
Vijayaraghavan S, Karakas C, Chen X, Doostan I, Raghavendra AS, Yi M, Amaravadi R, Hunt K, Tripathy D, Keyomarsi K. Abstract 2338: CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint Cancer Research. 77: 2338-2338. DOI: 10.1158/1538-7445.Am2017-2338 |
0.621 |
|
| 2017 |
Vijayaraghavan S, Doostan I, Carey JPW, Keyomarsi K. Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer Cancer Research. 77: 2060-2060. DOI: 10.1158/1538-7445.Am2017-2060 |
0.532 |
|
| 2016 |
Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin A, Adjapong O, Hortobogyi GN, Bondy ML, Thompson PA, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, ... Keyomarsi K, et al. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27881578 DOI: 10.1158/1078-0432.Ccr-16-2217 |
0.561 |
|
| 2016 |
Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research : McR. PMID 27671334 DOI: 10.1158/1541-7786.Mcr-16-0157 |
0.498 |
|
| 2016 |
Karakas C, Biernacka A, Bui T, Sahin A, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. The American Journal of Pathology. PMID 27182644 DOI: 10.1016/J.Ajpath.2016.02.024 |
0.604 |
|
| 2016 |
JavanMoghadam S, Zhang W, Hunt KK, Keyomarsi K. Estrogen Receptor Alpha is Cell Cycle-Regulated and Regulates the Cell Cycle in a Ligand-Dependent Fashion. Cell Cycle (Georgetown, Tex.). 0. PMID 27049344 DOI: 10.1080/15384101.2016.1166327 |
0.562 |
|
| 2016 |
Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Research. PMID 26928812 DOI: 10.1158/0008-5472.Can-15-1646 |
0.605 |
|
| 2016 |
Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, Keyomarsi K, Park JI. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nature Communications. 7: 10633. PMID 26843124 DOI: 10.1038/Ncomms10633 |
0.535 |
|
| 2016 |
Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 26826118 DOI: 10.1158/1535-7163.Mct-15-0519 |
0.547 |
|
| 2016 |
Franco HL, Nagari A, Xi Y, Li W, Richardson D, Tanaka K, Li J, Barton MC, Shi X, Keyomarsi K, Bedford MT, Li W, Dent SYR, Kraus WL. Abstract PR06: Analysis of enhancer transcription reveals novel gene regulatory networks in breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-Pr06 |
0.451 |
|
| 2016 |
Vijayaraghavan S, Keyomarsi K. Abstract 2989: An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer Cancer Research. 76: 2989-2989. DOI: 10.1158/1538-7445.Am2016-2989 |
0.639 |
|
| 2016 |
Carey JP, Keyomarsi K. Targeting the Cell Cycle in Breast Cancer Breast Diseases: a Year Book Quarterly. 27: 256-260. DOI: 10.1016/J.Breastdis.2016.10.023 |
0.545 |
|
| 2015 |
Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene. PMID 26279297 DOI: 10.1038/Onc.2015.301 |
0.549 |
|
| 2015 |
Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research : Bcr. 17: 87. PMID 26108797 DOI: 10.1186/S13058-015-0572-5 |
0.427 |
|
| 2015 |
Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs. 33: 890-4. PMID 25947565 DOI: 10.1007/S10637-015-0244-4 |
0.59 |
|
| 2015 |
Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 34: 3556-67. PMID 25195861 DOI: 10.1038/Onc.2014.284 |
0.561 |
|
| 2015 |
Carey JP, Keyomarsi K. Abstract B27: CDK inhibition impairs homologous recombination and induces PARP inhibitor sensitivity via loss of c-myc expression in TNBC Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B27 |
0.533 |
|
| 2015 |
Carey JP, Keyomarsi K. Abstract P6-03-09: Targeting the c-myc/E2F1 pathway in TNBC promotes a DNA damage dependent synthetic lethality Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-03-09 |
0.486 |
|
| 2015 |
Vijayaraghavan S, Keyomarsi K. Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-08-02 |
0.646 |
|
| 2015 |
Doostan I, Moulder SL, Hunt KK, Keyomarsi K. Abstract P5-05-05: Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-05-05 |
0.673 |
|
| 2015 |
Karakas C, Francis A, Yi M, Sahin A, Keyomarsi K, Hunt K. Abstract 3772: Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer Cancer Research. 75: 3772-3772. DOI: 10.1158/1538-7445.Am2015-3772 |
0.561 |
|
| 2015 |
Balaji K, Cardnell R, Diao L, Tong P, Mak M, Fan YH, Masrorpour F, Warner SL, Bearss DJ, Wistuba I, Mills GB, Heymach J, Keyomarsi K, Wang J, Byers LA. Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma Cancer Research. 75: 3579-3579. DOI: 10.1158/1538-7445.Am2015-3579 |
0.499 |
|
| 2015 |
Akli S, Yang D, Bui TN, Keyomarsi K. Abstract 3091: Targeting low molecular weight (LMW) cyclin E-Cdk2 pathway for the prevention of breast cancer Cancer Research. 75: 3091-3091. DOI: 10.1158/1538-7445.Am2015-3091 |
0.549 |
|
| 2015 |
Vijayaraghavan S, Keyomarsi K. Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer Cancer Research. 75: 1783-1783. DOI: 10.1158/1538-7445.Am2015-1783 |
0.618 |
|
| 2015 |
Balaji K, Su C, Akli S, Hunt KK, Keyomarsi K. Abstract 1422: Neutrophil Elastase plays a key role in epithelial-mesenchymal transition and metastasis in triple-negative breast cancers Cancer Research. 75: 1422-1422. DOI: 10.1158/1538-7445.Am2015-1422 |
0.577 |
|
| 2014 |
Karakas K, Ibrahim NK, Alvarez RH, Murray JL, Briones B, Simmons H, Keyomarsi K, Moulder SL. A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 163. PMID 28141097 DOI: 10.1200/Jco.2014.32.26_Suppl.163 |
0.607 |
|
| 2014 |
Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research : Bcr. 16: 3417. PMID 25551582 DOI: 10.1186/S13058-014-0497-4 |
0.554 |
|
| 2014 |
Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell Cycle (Georgetown, Tex.). 13: 2587-99. PMID 25486199 DOI: 10.4161/15384101.2015.942210 |
0.522 |
|
| 2014 |
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Keyomarsi K, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/Ncomms4459 |
0.356 |
|
| 2014 |
Francis AM, Carey JP, Alexander A, Keyomarsi K, Hunt KK. Abstract 1327: Targeting the RB-pathway in sarcoma: Utility of CDK4/6 inhibitors Cancer Research. 74: 1327-1327. DOI: 10.1158/1538-7445.Am2014-1327 |
0.353 |
|
| 2013 |
Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Research. 73: 5556-68. PMID 23955388 DOI: 10.1158/0008-5472.Can-13-0013 |
0.585 |
|
| 2013 |
Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 34: 2244-52. PMID 23722650 DOI: 10.1093/Carcin/Bgt186 |
0.787 |
|
| 2013 |
Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Molecular Oncology. 7: 647-68. PMID 23517670 DOI: 10.1016/J.Molonc.2013.02.008 |
0.496 |
|
| 2013 |
Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Research : Bcr. 15: R3. PMID 23320734 DOI: 10.1186/Bcr3374 |
0.816 |
|
| 2013 |
Litzenburger BC, Uray IP, Hill J, Keyomarsi K, Brown PH. Abstract A13: Mechanism-based chemoprevention of triple-negative breast cancer by blockade at multiple cell cycle regulatory points Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-A13 |
0.597 |
|
| 2013 |
Alexander A, Karakas C, Gong Y, Alvarez R, Ueno N, Keyomarsi K. Abstract P6-12-09: Targeting deregulated cyclin E in inflammatory breast cancer via sequential combination therapy Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P6-12-09 |
0.652 |
|
| 2012 |
Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. Plos Genetics. 8: e1002538. PMID 22479189 DOI: 10.1371/Journal.Pgen.1002538 |
0.833 |
|
| 2012 |
Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle (Georgetown, Tex.). 11: 1468-76. PMID 22441703 DOI: 10.4161/Cc.19882 |
0.588 |
|
| 2012 |
Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Research and Treatment. 132: 575-88. PMID 21695458 DOI: 10.1007/S10549-011-1638-4 |
0.828 |
|
| 2012 |
Akli S, Pelt CSV, Wenbin L, Keyomarsi K. Abstract 3283: Conditional Low-molecular-weight (LMW) cyclin E-induced mammary tumorigenesis Cancer Research. 72: 3283-3283. DOI: 10.1158/1538-7445.Am2012-3283 |
0.469 |
|
| 2012 |
Caruso JA, Karakas C, Hunt K, Keyomarsi K. Abstract 2466: Elafin, a serine protease inhibitor, is deregulated during breast cancer progression Cancer Research. 72: 2466-2466. DOI: 10.1158/1538-7445.Am2012-2466 |
0.539 |
|
| 2012 |
Siddiqui S, Keyomarsi K, Krishnamurthy S. Utility of Collodion Technique for Creating Cell Blocks of Breast Cancer Cell Lines Journal of the American Society of Cytopathology. 1: S12. DOI: 10.1016/J.Jasc.2012.08.019 |
0.519 |
|
| 2011 |
Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Therapy. 18: 510-9. PMID 21546925 DOI: 10.1038/Cgt.2011.20 |
0.808 |
|
| 2011 |
Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Research. 71: 3377-86. PMID 21385896 DOI: 10.1158/0008-5472.Can-10-4086 |
0.593 |
|
| 2011 |
Keyomarsi K, Efuet ET, Bui TN. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells Cell Biology and Toxicology. 27: 123-131. PMID 20853140 DOI: 10.1007/S10565-010-9175-1 |
0.406 |
|
| 2011 |
Mittendorf EA, Keyomarsi K, Hunt KK. Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients Breast Diseases: a Year Book Quarterly. 22: 266-267. DOI: 10.1016/J.Breastdis.2011.06.033 |
0.57 |
|
| 2010 |
Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Research. 70: 7125-36. PMID 20823156 DOI: 10.1158/0008-5472.Can-10-1547 |
0.617 |
|
| 2010 |
Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Research. 70: 5074-84. PMID 20530685 DOI: 10.1158/0008-5472.Can-09-4094 |
0.557 |
|
| 2010 |
Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Research. 70: 5085-95. PMID 20530684 DOI: 10.1158/0008-5472.Can-09-4095 |
0.532 |
|
| 2010 |
Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 29: 3896-907. PMID 20453888 DOI: 10.1038/Onc.2010.151 |
0.648 |
|
| 2010 |
Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle (Georgetown, Tex.). 9: 1122-30. PMID 20237430 DOI: 10.4161/Cc.9.6.10990 |
0.805 |
|
| 2010 |
Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1179-90. PMID 20145171 DOI: 10.1158/1078-0432.Ccr-09-1787 |
0.84 |
|
| 2010 |
Caruso JA, Hunt KK, Keyomarsi K. Abstract 3057: The serine protease inhibitor, elafin, exhibits novel tumor suppressor functions in the context of breast cancer Cancer Research. 70: 3057-3057. DOI: 10.1158/1538-7445.Am10-3057 |
0.61 |
|
| 2009 |
Fearmonti RM, Keyomarsi K, Hunt KK. Biomarkers in neoadjuvant trials. Cancer Treatment and Research. 147: 1-36. PMID 21461824 DOI: 10.1007/978-0-387-09463-2_8 |
0.434 |
|
| 2009 |
Mull BB, Cox J, Bui T, Keyomarsi K. Post-translational modification and stability of low molecular weight cyclin E. Oncogene. 28: 3167-3176. PMID 19561641 DOI: 10.1038/Onc.2009.182 |
0.497 |
|
| 2009 |
Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, ... ... Keyomarsi K, et al. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. Plos Medicine. 6: e1000068. PMID 19536326 DOI: 10.1371/Journal.Pmed.1000068 |
0.493 |
|
| 2009 |
Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3654-62. PMID 19470724 DOI: 10.1158/1078-0432.Ccr-08-3293 |
0.52 |
|
| 2009 |
Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Research. 69: 2817-25. PMID 19318554 DOI: 10.1158/0008-5472.Can-08-4182 |
0.457 |
|
| 2009 |
Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle (Georgetown, Tex.). 8: 1062-8. PMID 19305161 DOI: 10.4161/Cc.8.7.8119 |
0.832 |
|
| 2009 |
Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Research and Treatment. 115: 651-9. PMID 19107593 DOI: 10.1007/S10549-008-0266-0 |
0.547 |
|
| 2009 |
Bagheri-Yarmand R, Keyomarsi K. Overexpression of LMW cyclin E results in faster M phase progression via Cdc25C interaction leading to chromosome missegragation in breast cancer cells. Cancer Research. 69: 5032. DOI: 10.1158/0008-5472.Sabcs-5032 |
0.605 |
|
| 2009 |
Akli S, Pelt CV, Bui T, Keyomarsi K. CDK2 is required for LMW-cyclin E mediated murine mammary tumorigenesis. Cancer Research. 69: 2007. DOI: 10.1158/0008-5472.Sabcs-2007 |
0.541 |
|
| 2009 |
Akli S, Keyomarsi K. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype Breast Diseases: a Year Book Quarterly. 20: 64-65. DOI: 10.1016/S1043-321X(09)79226-4 |
0.487 |
|
| 2009 |
Bedrosian I, Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K. QS295. Cyclin E Deregulation Is an Early Event in the Development of Breast Cancer Journal of Surgical Research. 151: 295. DOI: 10.1016/J.Jss.2008.11.601 |
0.544 |
|
| 2008 |
Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Research. 68: 7966-74. PMID 18829554 DOI: 10.1158/0008-5472.Can-08-1333 |
0.468 |
|
| 2008 |
Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle (Georgetown, Tex.). 7: 2434-40. PMID 18677105 DOI: 10.4161/Cc.6364 |
0.463 |
|
| 2008 |
Mittendorf EA, Wingate H, Liu Y, Keyomarsi K, Hunt KK. QS287. HER2 Regulates Expression of Low Molecular Weight Cyclin E Isoforms in Breast Cancer Journal of Surgical Research. 144: 380-381. DOI: 10.1016/J.Jss.2007.12.538 |
0.808 |
|
| 2007 |
Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Research. 67: 11272-83. PMID 18056453 DOI: 10.1158/0008-5472.Can-07-2322 |
0.37 |
|
| 2007 |
Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel? Advances in Experimental Medicine and Biology. 608: 52-69. PMID 17993232 DOI: 10.1007/978-0-387-74039-3_4 |
0.629 |
|
| 2007 |
Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4800-6. PMID 17699858 DOI: 10.1158/1078-0432.Ccr-07-0142 |
0.505 |
|
| 2007 |
Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Research. 67: 7212-22. PMID 17671189 DOI: 10.1158/0008-5472.Can-07-0599 |
0.579 |
|
| 2006 |
McGahren-Murray M, Terry NH, Keyomarsi K. The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein. Cancer Research. 66: 9744-53. PMID 17018634 DOI: 10.1158/0008-5472.Can-06-1809 |
0.544 |
|
| 2006 |
Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer Journal of Cellular Physiology. 209: 686-694. PMID 17001684 DOI: 10.1002/Jcp.20818 |
0.565 |
|
| 2006 |
Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle (Georgetown, Tex.). 5: 1654-61. PMID 16861913 DOI: 10.4161/Cc.5.15.3007 |
0.824 |
|
| 2006 |
Efuet ET, Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Research. 66: 1040-51. PMID 16424040 DOI: 10.1158/0008-5472.Can-05-3416 |
0.458 |
|
| 2005 |
Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 102: 12519-24. PMID 16116079 DOI: 10.1073/Pnas.0505641102 |
0.488 |
|
| 2005 |
Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in Cancer Biology. 15: 319-26. PMID 16043362 DOI: 10.1016/J.Semcancer.2005.04.007 |
0.476 |
|
| 2005 |
Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. The Journal of Biological Chemistry. 280: 15148-57. PMID 15708847 DOI: 10.1074/Jbc.M409789200 |
0.796 |
|
| 2005 |
Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Research. 65: 692-7. PMID 15705861 |
0.384 |
|
| 2005 |
Keyomarsi K, Akli S. Targeting the cell cycle for prognosis and therapy of breast cancer Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1067 |
0.584 |
|
| 2004 |
Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Research : Bcr. 6: 188-91. PMID 15318923 DOI: 10.1186/Bcr905 |
0.611 |
|
| 2004 |
Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 59: 928-42. PMID 15234026 DOI: 10.1016/J.Ijrobp.2004.03.005 |
0.415 |
|
| 2004 |
Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Research. 64: 3198-208. PMID 15126360 DOI: 10.1158/0008-5472.Can-03-3672 |
0.829 |
|
| 2004 |
Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 23: 2648-57. PMID 15007381 DOI: 10.1038/Sj.Onc.1207408 |
0.562 |
|
| 2004 |
Harwell RM, Mull BB, Porter DC, Keyomarsi K. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. The Journal of Biological Chemistry. 279: 12695-705. PMID 14701826 DOI: 10.1074/Jbc.M313407200 |
0.608 |
|
| 2003 |
Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Progress in Cell Cycle Research. 5: 527-32. PMID 14593747 |
0.356 |
|
| 2003 |
Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biology & Therapy. 2: S38-47. PMID 14508079 DOI: 10.4161/Cbt.201 |
0.604 |
|
| 2003 |
Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle (Georgetown, Tex.). 2: 461-6. PMID 12963845 DOI: 10.4161/Cc.2.5.464 |
0.816 |
|
| 2003 |
Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nature Medicine. 9: 152. PMID 12563321 DOI: 10.1038/Nm0203-152 |
0.567 |
|
| 2002 |
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. The New England Journal of Medicine. 347: 1566-75. PMID 12432043 DOI: 10.1056/Nejmoa021153 |
0.614 |
|
| 2001 |
Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ. Phosphorylation-dependent ubiquitination of cyctin E by the SCFFbw7 ubiquitin ligase Science. 294: 173-177. PMID 11533444 DOI: 10.1126/Science.1065203 |
0.47 |
|
| 2001 |
Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Molecular and Cellular Biology. 21: 6254-69. PMID 11509668 DOI: 10.1128/Mcb.21.18.6254-6269.2001 |
0.558 |
|
| 2001 |
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 20: 147-55. PMID 11313944 DOI: 10.1038/Sj.Onc.1204062 |
0.487 |
|
| 2001 |
Chen X, Lowe M, Herliczek T, Hall MJ, Danes C, Lawrence DA, Keyomarsi K. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. Journal of the National Cancer Institute. 92: 1999-2008. PMID 11121462 DOI: 10.1093/Jnci/92.24.1999 |
0.484 |
|
| 2000 |
Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity Nucleic Acids Research. 28. PMID 11095697 DOI: 10.1093/Nar/28.23.E101 |
0.515 |
|
| 2000 |
Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K. Activation of the Estrogen-Signaling Pathway by p21WAF1/CIP1 in Estrogen Receptor-Negative Breast Cancer Cells Journal of the National Cancer Institute. 92: 1403-1413. PMID 10974076 DOI: 10.1093/Jnci/92.17.1403 |
0.53 |
|
| 2000 |
Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Molecular and Cellular Endocrinology. 162: 167-80. PMID 10854710 DOI: 10.1016/S0303-7207(00)00194-5 |
0.409 |
|
| 2000 |
Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Research. 28: 2108-13. PMID 10773079 DOI: 10.1093/Nar/28.10.2108 |
0.38 |
|
| 1999 |
Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent Oncogene. 18: 5691-5702. PMID 10577141 DOI: 10.1038/Sj.Onc.1202948 |
0.535 |
|
| 1999 |
Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K. The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Experimental Cell Research. 252: 211-223. PMID 10502413 DOI: 10.1006/Excr.1999.4620 |
0.502 |
|
| 1999 |
Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase Proceedings of the National Academy of Sciences of the United States of America. 96: 7797-7802. PMID 10393901 DOI: 10.1073/Pnas.96.14.7797 |
0.43 |
|
| 1998 |
Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 17: 2393-2402. PMID 9811471 DOI: 10.1038/Sj.Onc.1202322 |
0.556 |
|
| 1998 |
Bacus S, Kiffmeyer B, Gudkov A, Keyomarsi K. Heregulin and doxorubicin activate a p53 dependent pathway in cancer cells whereas taxol depends on activation of the MAP kinase pathway European Journal of Cancer. 34: S30. DOI: 10.1016/S0959-8049(98)80124-X |
0.419 |
|
| 1997 |
Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Progress in Cell Cycle Research. 3: 171-191. PMID 9552414 DOI: 10.1007/978-1-4615-5371-7_14 |
0.553 |
|
| 1997 |
Stover PJ, Chen LH, Suh JR, Stover DM, Keyomarsi K, Shane B. Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene. The Journal of Biological Chemistry. 272: 1842-8. PMID 8999870 DOI: 10.1074/Jbc.272.3.1842 |
0.306 |
|
| 1996 |
Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, Decaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer Proceedings of the National Academy of Sciences of the United States of America. 93: 15215-15220. PMID 8986790 DOI: 10.1073/Pnas.93.26.15215 |
0.578 |
|
| 1996 |
Dou QP, Pardee AB, Keyomarsi K. Cyclin E -- a better prognostic marker for breast cancer than cyclin D? Nature Medicine. 2: 254. PMID 8612208 DOI: 10.1038/Nm0396-254A |
0.549 |
|
| 1995 |
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E. Inhibition of cyclin-dependent kinases by p21. Molecular Biology of the Cell. 6: 387-400. PMID 7626805 DOI: 10.1091/Mbc.6.4.387 |
0.407 |
|
| 1993 |
Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells Proceedings of the National Academy of Sciences of the United States of America. 90: 1112-1116. PMID 8430082 DOI: 10.1073/Pnas.90.3.1112 |
0.588 |
|
| 1993 |
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell. 75: 805-816. PMID 8242751 DOI: 10.1016/0092-8674(93)90499-G |
0.442 |
|
| 1992 |
Pardee AB, Keyomarsi K. Modification of cell proliferation with inhibitors Current Opinion in Cell Biology. 4: 186-191. PMID 1376129 DOI: 10.1016/0955-0674(92)90031-7 |
0.394 |
|
| 1992 |
Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proceedings of the National Academy of Sciences of the United States of America. 89: 2504-8. PMID 1372446 DOI: 10.1073/Pnas.89.6.2504 |
0.429 |
|
| 1992 |
Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager R. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. The Journal of Cell Biology. 118: 1213-21. PMID 1324944 DOI: 10.1083/Jcb.118.5.1213 |
0.435 |
|
| 1990 |
Fridovich-Keil JL, Hansen LJ, Keyomarsi K, Pardee AB. Progression through the cell cycle: An overview American Review of Respiratory Disease. 142: S3-S6. PMID 2252273 DOI: 10.1164/Ajrccm/142.6_Pt_2.S3 |
0.392 |
|
| 1988 |
Moran RG, Keyomarsi K, Patel R. Tumor Cell Responses to Inhibition of Thymidylate Synthase Advances in Experimental Medicine and Biology. 244: 71-83. PMID 2977717 DOI: 10.1007/978-1-4684-5607-3_7 |
0.645 |
|
| 1986 |
Moran RG, Keyomarsi K, Colman PD. Preparation of (6S)-5-Formyltetrahydrofolate Labeled at High Specific Activity with 14C and 3H Methods in Enzymology. 122: 309-312. PMID 3517564 DOI: 10.1016/0076-6879(86)22185-0 |
0.55 |
|
| Show low-probability matches. |